【康弘药业:子公司收到KH813注射液临床试验批准通知书】康弘药业(002773.SZ)公告称,公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意KH813注射液按生物类似药开展临床试验。KH813注射液是康弘生物研发的帕博利珠单抗生物类似药,主要用于治疗多种晚期实体瘤。由于药品研发存在不确定性,投资者需谨慎决策并注意投资风险。

金融界
Jun 30, 2025
康弘药业(002773.SZ)公告称,公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意KH813注射液按生物类似药开展临床试验。KH813注射液是康弘生物研发的帕博利珠单抗生物类似药,主要用于治疗多种晚期实体瘤。由于药品研发存在不确定性,投资者需谨慎决策并注意投资风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10